sicklecellanemianews1d
Desferal, to prevent iron overload in SCD patients, acquired by Mitem
Mitem Pharma acquired from Novartis worldwide rights to Desferal, commonly used to lower excessive iron levels induced by ...
sicklecellanemianews5d
At times, stepping back from advocacy is the wise thing to do
Columnist Mary Shaniqua, returning from her post-wedding activities, has learned that stepping back from advocacy obligations ...
sicklecellanemianews6d
Stroke rate rising for adults, children with SCD in US: Study
The stroke rate among adults and children with sickle cell disease in the U.S. is rising, indicating a need for greater ...
sicklecellanemianews8d
Pfizer withdraws Oxbryta from global markets, cites safety concerns
Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.
sicklecellanemianews9d
Steve Bryson, PhD, science writer
The U.S. Food and Drug Administration (FDA) gave the greenlight for Iomab-ACT, a potentially less toxic conditioning regimen, to be tested in people with sickle cell disease (SCD) undergoing a stem ...
sicklecellanemianews15d
Sigma Gamma Rho Sorority pledges $2M to hospital treating sickle cell
The women's sorority plans to donate $2 million by 2028 to St. Jude Children's Research Hospital, which offers care at no ...